ngram’s Post

#ConcertAI and Caris Life Sciences have formed a strategic partnership with AbbVie to accelerate #oncology research and #clinicaltrials. Utilizing #AI and #ML, they will leverage extensive clinical and #genomic databases to optimize #drugdevelopment and precision #medicine. This collaboration aims to transform #cancer treatment, focusing on developing #targetedtherapies through advanced #technology and data analysis. Jeff Elton, CEO of ConcertAI, highlighted the role of AI/ML in #drugdiscovery stating: "This partnership furthers our goals of enabling causal biological inferences, where multi-modal data can be integrated with AI/ML-based approaches in #drug discovery, translation and development, to accelerate oncology pipelines, and allow our #biopharma partners to discover and deliver better medicines faster." https://lnkd.in/d69fv9w3

Artificial Intelligence is helping researchers quantify and track aging in cancer drug development. Here's how. #AI #ML #futurism #IntelligenceFactory #digitaltransformation #DX https://lnkd.in/gASeFacZ

Join this webinar to explore how incorporating biomarker strategies and NGS and AI approaches, at the early stages of preclinical research can enhance the drug discovery and development process. These are key components of modern personalized medicine strategies providing many benefits for early cancer detection, recruitment, and stratifications of patients into subgroups, treatment selection, minimal residual disease surveillance and monitoring. #AI #Biomarkers #PersonalizedMedicine

Innovating Alzheimer’s Drug Discovery Using AI and Knowledge Graphs🔬💊 In collaboration with St. John's Cancer Institute, Wisecube is trying to reshape Alzheimer's drug discovery. By fusing AI and Knowledge Graphs, we're navigating the complex terrain of this neurodegenerative disease to uncover new treatments and repurpose existing drugs.  Our dual approach accelerates the identification of promising compounds, overcoming the challenges of molecular complexity, prediction accuracy, and blood-brain barrier crossing.  Dive into our case study to explore how we're leveraging cutting-edge technology to bring hope in the fight against Alzheimer's. Read the full story here> https://lnkd.in/eZY5ttAP #AIDrugDiscovery #AlzheimersResearch #DrugDiscovery #BiotechAI

Exciting Developments in AI-Driven Precision Oncology! Thrilled to share insights into the ever-evolving landscape of AI-driven personalized drug and cell therapies within precision oncology. 🧬 This article sheds light on the regulatory challenges accompanying these advancements and emphasizes the imperative need for innovative regulatory strategies to match the swift progress in technology. Key Points: 1️⃣ Rise of AI in Precision Oncology: Witness the integration of AI into precision oncology, demanding unconventional regulatory approaches. 2️⃣ Navigating Regulatory Challenges: The paper delves into specific challenges and proposes insightful solutions for regulatory adaptation, paving the way for a seamless transition in this dynamic field. Join the conversation and stay ahead in the world of cutting-edge medical advancements! 🌐✨ #PrecisionOncology #AIinMedicine #RegulatoryInnovation #HealthTech #FutureOfMedicine#SamD #AI/ML #medicaldevices #regulatoryaffairs 📚 Read the full article here - https://lnkd.in/e3CAeEK4 Let's connect and explore the future of healthcare together! Feel free to follow for more insightful articles on the intersection of technology and medicine. #HealthcareInnovation #LinkedInArticle #FollowMeForUpdates

TechBio Innovator Etcembly Reveals World’s First Generative AI-designed Bispecific T Cell Engager With Picomolar Affinity British techbio innovator Etcembly is coming out of stealth mode, kickstarting the next generation of immunotherapies with a pipeline of best-in-class T cell receptor (TCR) therapeutics designed using generative AI. The company’s lead therapeutic programme, ETC-101, is the world’s first AI-designed bispecific T cell engager. It targets PRAME, a validated antigen present in many cancers. The lead asset currently demonstrates single digit picomolar affinity – a million-fold higher affinity than the native receptor – with no known cross-reactivity. Etcembly has advanced ETC-101 to this stage in 11 months, compared with 2+ years for conventional TCR pipelines. Future programmes should be even faster now the platform is established, and include first-in-class assets against undisclosed targets in oncology and autoimmune disease. Read more: https://lnkd.in/dGJvY4PQ